ArticleExpert review of ophthalmology2008
Ocular toxicity of fludarabine: a purine analog.
Article in Expert review of ophthalmology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.Bone marrow transplantation · 2011Trial
- Unlocking nature's potential: Soursop in the battle against resistant acute myeloid leukemia.Biochemistry and biophysics reports · 2025Review
- Tumor-Infiltrating Lymphocyte Cell Therapy for the Treatment of Advanced Melanoma: From Patient Identification to Posttreatment Management.Journal of the advanced practitioner in oncology · 2025Review
- Advancements in vaccine development and therapeutic approaches for severe fever with Thrombocytopenia Syndrome.Frontiers in cellular and infection microbiology · 2025Review
- Design of an innovative aptasensor for the detection of chemotherapeutic drug Fludarabine phosphate.Scientific reports · 2024Article
- Ophthalmic Manifestations in Patients with Blood Malignancies.Hematology reports · 2024Review
- Antiviral Treatment Options for Severe Fever with Thrombocytopenia Syndrome Infections.Infectious diseases and therapy · 2022Review
- [Maculopathy in sickle cell disease].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- Visual loss secondary to fludarabine toxicity: optical coherence tomography findings in two patients.Eye (London, England) · 2019Article
- Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report.Clinical case reports · 2015Article
- Purine nucleoside phosphorylase targeted by annexin v to breast cancer vasculature for enzyme prodrug therapy.PloS one · 2013Article
- Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
- Rapid vision loss associated with fludarabine administration.Retina (Philadelphia, Pa.) · 2010Article
- Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.Drug design, development and therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The purine analogs, fludarabine and cladribine represent an important class of chemotherapy agents used to treat a broad spectrum of lymphoid malignancies. Their toxicity profiles include dose-limiting myelosuppression, immunosuppression, opportunistic infection and severe neurotoxicity. This review summarizes the neurotoxicity of high- and standard-dose fludarabine, focusing on the clinical and pathological manifestations in the eye. The mechanisms of ocular toxicity are probably multifactorial. With increasing clinical use, an awareness of the neurological and ocular vulnerability, particularly to fludarabine, is important owing to the potential for life- and sight-threatening consequences.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.